Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Publication Date

2023

Content Type

Article

PubMed ID:

38072514

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS